Clinical Trial Update: Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating different doses of TreeMATA for induction of immunogenicity in people with tree pollen allergy. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Pollen Allergy

Drugs mentioned

• TreeMATA

Snippet

Sponsor: Allergy Therapeutics | Conditions: Type I Hypersensitivity | Phase 2 | Status: COMPLETED